首页 > 最新文献

Visceral Medicine最新文献

英文 中文
Usefulness of Liver Uptake Rate Constant in 99mTc-GSA Scintigraphy for the Risk Stratification of Patients Undergoing Hepatectomy: A New Method for Calculation. 99mTc-GSA闪烁成像中肝脏摄取率常数对肝切除术患者风险分层的有用性:一种新的计算方法。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-12-01 Epub Date: 2022-08-04 DOI: 10.1159/000525892
Yuzo Yamamoto, Yoshihiro Abukawa, Kimihiko Sato, Go Watanabe, Yasuhiko Nakagawa, Manabu Hashimoto, Masatake Iida

Introduction: The use of technetium 99m diethylenetriaminepentaacetic acid-galactosyl human serum albumin (99mTc-GSA) scintigraphy parameters, HH15 and LHL15, in assessing the future liver remnant function is not expedient because of their nonlinear behaviour against liver volume. Uptake rate constant for the binding of 99mTc-GSA to asialoglycoprotein receptors is probably more favourable, but the reported calculation methods are complex. We devised a simple method to calculate the uptake rate constant, KrGSA.

Methods: Radioactivity counts for the entire liver and heart regions were extracted at 10, 20, and 30 min. Using whole liver and heart volumes measured from single-photon emission computed tomography images, free radioactivity corresponding to the liver blood pool was subtracted. The time activity curve was fitted to the equation L(t) = L(∞) × [1 - Exp (-kt)] using Microsoft Office Excel (add-in free programme Solver)®, where L(∞) is the count at plateau level and k denotes KrGSA.

Results: KrGSA values accurately identified liver cirrhosis and were similar to the KICG. The areas under the curve for KrGSA and KICG in the receiver operating characteristic analysis were 0.808 and 0.795, respectively, and a good correlation was seen between KrGSA and KICG.

Discussion/conclusion: KrGSA can be utilized as an alternative to KICG in assessing the future liver remnant function.

99m二乙基三胺五乙酸-半乳糖人血清白蛋白(99mTc-GSA)扫描参数HH15和LHL15在评估未来肝残功能时并不合适,因为它们与肝体积呈非线性关系。99mTc-GSA与亚洲糖蛋白受体结合的摄取速率常数可能更有利,但报道的计算方法复杂。我们设计了一种简单的方法来计算吸收速率常数KrGSA。方法:在10,20,30min提取全肝和心脏区域的放射性计数。利用单光子发射计算机断层扫描图像测量的全肝和心脏体积,减去肝脏血池对应的自由放射性。时间活度曲线拟合公式为L(t) = L(∞)× [1 - Exp (-kt)],使用Microsoft Office Excel(插件免费程序Solver)®,其中L(∞)为平台水平计数,k为KrGSA。结果:KrGSA值能准确识别肝硬化,与KICG值相近。在受试者工作特征分析中,KrGSA和KICG的曲线下面积分别为0.808和0.795,KrGSA与KICG具有良好的相关性。讨论/结论:KrGSA可作为评估未来肝残功能的替代方法。
{"title":"Usefulness of Liver Uptake Rate Constant in <sup>99m</sup>Tc-GSA Scintigraphy for the Risk Stratification of Patients Undergoing Hepatectomy: A New Method for Calculation.","authors":"Yuzo Yamamoto, Yoshihiro Abukawa, Kimihiko Sato, Go Watanabe, Yasuhiko Nakagawa, Manabu Hashimoto, Masatake Iida","doi":"10.1159/000525892","DOIUrl":"10.1159/000525892","url":null,"abstract":"<p><strong>Introduction: </strong>The use of technetium 99m diethylenetriaminepentaacetic acid-galactosyl human serum albumin (<sup>99m</sup>Tc-GSA) scintigraphy parameters, HH15 and LHL15, in assessing the future liver remnant function is not expedient because of their nonlinear behaviour against liver volume. Uptake rate constant for the binding of <sup>99m</sup>Tc-GSA to asialoglycoprotein receptors is probably more favourable, but the reported calculation methods are complex. We devised a simple method to calculate the uptake rate constant, K<i>r</i>GSA.</p><p><strong>Methods: </strong>Radioactivity counts for the entire liver and heart regions were extracted at 10, 20, and 30 min. Using whole liver and heart volumes measured from single-photon emission computed tomography images, free radioactivity corresponding to the liver blood pool was subtracted. The time activity curve was fitted to the equation <i>L</i>(<i>t</i>) = <i>L</i>(∞) × [1 - Exp (-<i>kt</i>)] using Microsoft Office Excel (add-in free programme Solver)®, where <i>L</i>(∞) is the count at plateau level and <i>k</i> denotes K<i>r</i>GSA.</p><p><strong>Results: </strong>K<i>r</i>GSA values accurately identified liver cirrhosis and were similar to the KICG. The areas under the curve for K<i>r</i>GSA and KICG in the receiver operating characteristic analysis were 0.808 and 0.795, respectively, and a good correlation was seen between K<i>r</i>GSA and KICG.</p><p><strong>Discussion/conclusion: </strong>K<i>r</i>GSA can be utilized as an alternative to KICG in assessing the future liver remnant function.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 6","pages":"400-407"},"PeriodicalIF":1.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801322/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10523437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
PharmaNews
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-12-01 DOI: 10.1159/000528292
I. Blumenstein
Auf dem diesjährigen Anaemia Day von Pharmacosmos in Kopenhagen diskutierte PD Dr. med. Irina Blumenstein die Bedeutung von Eisenmangel und Eisenmangelanämie für die Lebensqualität von Patient*innen mit chronisch-entzündlichen Darmerkrankungen (CED). Sie stellte dazu aktuelle Ergebnisse der Studie PHOSPHAREIBD vor, die nach Verabreichung des intravenösen (i.v.) Eisenpräparats Eisen(III)-Derisomaltose (MonoFer®) stärkere Verbesserungen des FACIT-Fatigue-Scores bei CED-Patient*innen zeigen als nach Eisencarboxymaltose [1].
在今年的哥本哈根法克斯医院的阿纳米尼亚日上报告在进行静脉注射后Eisenpräparats铁(III) -Derisomaltose (MonoFer®)可以进一步改进FACIT-Fatigue-Scores CED-Patient *里面秀恩爱时Eisencarboxymaltose [1] .
{"title":"PharmaNews","authors":"I. Blumenstein","doi":"10.1159/000528292","DOIUrl":"https://doi.org/10.1159/000528292","url":null,"abstract":"Auf dem diesjährigen Anaemia Day von Pharmacosmos in Kopenhagen diskutierte PD Dr. med. Irina Blumenstein die Bedeutung von Eisenmangel und Eisenmangelanämie für die Lebensqualität von Patient*innen mit chronisch-entzündlichen Darmerkrankungen (CED). Sie stellte dazu aktuelle Ergebnisse der Studie PHOSPHAREIBD vor, die nach Verabreichung des intravenösen (i.v.) Eisenpräparats Eisen(III)-Derisomaltose (MonoFer®) stärkere Verbesserungen des FACIT-Fatigue-Scores bei CED-Patient*innen zeigen als nach Eisencarboxymaltose [1].","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 1","pages":"409 - 409"},"PeriodicalIF":1.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42041403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mirizzi Syndrome: Is There a Place for Minimally Invasive Surgery? Mirizzi综合征:微创手术有一席之地吗?
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-12-01 Epub Date: 2022-08-10 DOI: 10.1159/000525557
Aistė Gulla, Marta Jasaitė, Laura Bilotaitė, Kestutis Strupas

Objectives: Mirizzi syndrome (MS) is a condition when an impacted stone in the cystic duct or the Hartmann's pouch due to its extrinsic compression and concomitant inflammation causes an obstruction of the common bile duct. Laparotomy was the preferred surgical technique to treat this syndrome. However, with advances in technologies, an increasing number of surgeons are starting to choose minimally invasive surgery. The objective of this study is to review existing literature relating to minimally invasive surgery treatment of MS.

Methods: PubMed and ClinicalKey were used to search and identify relevant articles since January 2000 to December 2020. The following keywords were applied: Mirizzi syndrome, laparoscopy, minimally invasive. The criteria for exclusion were applied: case reports with less than 2 patients, nonsurgical treatments, and reviews were excluded from this study.

Results: Thirty-two articles were identified for analysis, 17 (540 patients in total) of these articles fulfilled the inclusion criteria: 8 retrospective studies, 4 case series, and 5 prospective studies. In the analyzed cohort, 295 patients were treated laparoscopically. Out of 17 articles included in the manuscript, 14 articles provided the information on minimally invasive surgery approach. There were 221 minimally invasive surgeries, out of which 143 (64.7%) were successful, thus according to the type of MS: MS I-175 (79.2%), successful 105 (60%); MS II-40 (18%), successful 32 (80%); MS III-6 (2.7%), successful 6 (100%). The mean conversion rate from laparoscopic to open surgery was 26.2% (range 0-67%), and the median complication rate in seventeen studies was 18.1% (range 0-40%), respectively. The female/male ratio was 1.2:1, and the median age in fifteen studies providing overall data on age was 57.4 years (range 40.1-70.1 years).

Conclusions: Current evidence presents that open surgery remains the main treatment for MS. Minimally invasive approaches are feasible, safe, and are associated with short-term recovery, significant differences in the operation time and blood loss during operation. However, minimally invasive approaches are mainly restricted to selected patients with type I MS.

目的:Mirizzi综合征(MS)是指胆囊管或哈特曼袋内的结石由于其外在压迫和伴随的炎症导致胆总管梗阻。剖腹手术是治疗该综合征的首选手术技术。然而,随着技术的进步,越来越多的外科医生开始选择微创手术。方法:使用PubMed和ClinicalKey检索2000年1月至2020年12月期间的相关文章。应用以下关键词:Mirizzi综合征,腹腔镜,微创。采用排除标准:少于2例患者的病例报告、非手术治疗和综述被排除在本研究之外。结果:共纳入32篇文章,其中17篇(540例患者)符合纳入标准:8项回顾性研究,4项病例系列研究,5项前瞻性研究。在分析的队列中,295例患者接受腹腔镜治疗。在17篇文章中,14篇文章提供了微创手术入路的信息。微创手术221例,成功143例(64.7%),按MS类型分:MS I-175例(79.2%),成功105例(60%);MS II-40(18%),成功32 (80%);MS III-6(2.7%),成功6例(100%)。从腹腔镜手术到开放手术的平均转换率为26.2%(范围0-67%),17项研究的中位并发症发生率分别为18.1%(范围0-40%)。女性/男性比例为1.2:1,15项研究提供的年龄总体数据的中位年龄为57.4岁(范围40.1-70.1岁)。结论:目前的证据表明,开放手术仍然是ms的主要治疗方法,微创方法可行、安全、短期恢复、手术时间和术中出血量有显著差异。然而,微创入路主要局限于选定的I型MS患者。
{"title":"Mirizzi Syndrome: Is There a Place for Minimally Invasive Surgery?","authors":"Aistė Gulla, Marta Jasaitė, Laura Bilotaitė, Kestutis Strupas","doi":"10.1159/000525557","DOIUrl":"10.1159/000525557","url":null,"abstract":"<p><strong>Objectives: </strong>Mirizzi syndrome (MS) is a condition when an impacted stone in the cystic duct or the Hartmann's pouch due to its extrinsic compression and concomitant inflammation causes an obstruction of the common bile duct. Laparotomy was the preferred surgical technique to treat this syndrome. However, with advances in technologies, an increasing number of surgeons are starting to choose minimally invasive surgery. The objective of this study is to review existing literature relating to minimally invasive surgery treatment of MS.</p><p><strong>Methods: </strong>PubMed and ClinicalKey were used to search and identify relevant articles since January 2000 to December 2020. The following keywords were applied: Mirizzi syndrome, laparoscopy, minimally invasive. The criteria for exclusion were applied: case reports with less than 2 patients, nonsurgical treatments, and reviews were excluded from this study.</p><p><strong>Results: </strong>Thirty-two articles were identified for analysis, 17 (540 patients in total) of these articles fulfilled the inclusion criteria: 8 retrospective studies, 4 case series, and 5 prospective studies. In the analyzed cohort, 295 patients were treated laparoscopically. Out of 17 articles included in the manuscript, 14 articles provided the information on minimally invasive surgery approach. There were 221 minimally invasive surgeries, out of which 143 (64.7%) were successful, thus according to the type of MS: MS I-175 (79.2%), successful 105 (60%); MS II-40 (18%), successful 32 (80%); MS III-6 (2.7%), successful 6 (100%). The mean conversion rate from laparoscopic to open surgery was 26.2% (range 0-67%), and the median complication rate in seventeen studies was 18.1% (range 0-40%), respectively. The female/male ratio was 1.2:1, and the median age in fifteen studies providing overall data on age was 57.4 years (range 40.1-70.1 years).</p><p><strong>Conclusions: </strong>Current evidence presents that open surgery remains the main treatment for MS. Minimally invasive approaches are feasible, safe, and are associated with short-term recovery, significant differences in the operation time and blood loss during operation. However, minimally invasive approaches are mainly restricted to selected patients with type I MS.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 6","pages":"369-375"},"PeriodicalIF":1.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10523436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
PharmaNews PharmaNews
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-12-01 DOI: 10.1159/000528289
Besonders bei Patient*innen mit Zivilisationskrankheiten wie Typ-2-Diabetes sollte immer das Vorliegen einer nichtalkoholischen Fettleber (NAFLD) abgeklärt werden, sagt die Deutsche Gesellschaft für Endokrinologie e.V. (DGE). Unbehandelt könne eine NAFLD über Entzündung und bindegewebigen Umbau zu einer Zirrhose und schließlich zum Versagen des wichtigen Stoffwechselorgans führen. Zu der Gruppe mit hohem Risiko für eine NAFLD gehören nicht nur Menschen mit Diabetes mellitus Typ 2, sondern auch solche mit Adipositas, arterieller Hypertonie, Fettstoffwechselstörungen oder metabolischem Syndrom. Weniger bekannt ist, dass auch typische endokrinologische Erkrankungen wie das polyzystische Ovarialsyndrom (PCOS), das Cushing-Syndrom und die Akromegalie Risikofaktoren darstellen. All diese Gesundheitsstörungen werden von Endokrinologinnen und Endokrinologen mitbehandelt. Für eine leitliniengerechte und fachübergreifende Versorgung schließt sich die DGE nun einem Bündnis mehrerer Fachgesellschaften und Organisationen, die mit NAFLD und ihren Folgeerkrankungen befasst sind, an. Dies beinhaltet auch die Forderung nach Aufnahme des Erkrankungskomplexes in bestehende Disease Management-Programme (DMP).
德国内分泌学协会(DGE)表示,对于那些患了2型糖尿病一类的平民疾病的病人,内分泌学应总是找不含的脂肪肝脏来解决这些问题。NAFLD如果不治疗,就会导致炎症和膝组织代谢,并导致主要代谢器官的衰竭。NAFLD的高风险群体中不仅包括有糖尿病的2型患者,还包括有肥胖症、动脉高血压、脂肪代谢失调和新陈代谢综合症的人。没人知道内分泌病(PCOS)、库辛综合征和杂技疾病风险因素等典型的内分泌病患者。内分泌学家和内分泌学家都在治疗这些健康问题。为确保繁荣和专业间支持,中央银行现在加入了由致力于全国民主阵线及其后续疾病的多个专业社会和组织的联盟。这包括要求把综合疾病发病率纳入现有管理方案(DMP)。
{"title":"PharmaNews","authors":"","doi":"10.1159/000528289","DOIUrl":"https://doi.org/10.1159/000528289","url":null,"abstract":"Besonders bei Patient*innen mit Zivilisationskrankheiten wie Typ-2-Diabetes sollte immer das Vorliegen einer nichtalkoholischen Fettleber (NAFLD) abgeklärt werden, sagt die Deutsche Gesellschaft für Endokrinologie e.V. (DGE). Unbehandelt könne eine NAFLD über Entzündung und bindegewebigen Umbau zu einer Zirrhose und schließlich zum Versagen des wichtigen Stoffwechselorgans führen. Zu der Gruppe mit hohem Risiko für eine NAFLD gehören nicht nur Menschen mit Diabetes mellitus Typ 2, sondern auch solche mit Adipositas, arterieller Hypertonie, Fettstoffwechselstörungen oder metabolischem Syndrom. Weniger bekannt ist, dass auch typische endokrinologische Erkrankungen wie das polyzystische Ovarialsyndrom (PCOS), das Cushing-Syndrom und die Akromegalie Risikofaktoren darstellen. All diese Gesundheitsstörungen werden von Endokrinologinnen und Endokrinologen mitbehandelt. Für eine leitliniengerechte und fachübergreifende Versorgung schließt sich die DGE nun einem Bündnis mehrerer Fachgesellschaften und Organisationen, die mit NAFLD und ihren Folgeerkrankungen befasst sind, an. Dies beinhaltet auch die Forderung nach Aufnahme des Erkrankungskomplexes in bestehende Disease Management-Programme (DMP).","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 1","pages":"410 - 413"},"PeriodicalIF":1.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45775952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Implications of Postoperative Hyperamylasemia after Partial Pancreaticoduodenectomy. 胰十二指肠部分切除术后高淀粉酶血症的临床意义。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-12-01 Epub Date: 2022-10-24 DOI: 10.1159/000526495
Ioannis Mintziras, Sabine Wächter, Jerena Manoharan, Veit Kanngiesser, Elisabeth Maurer, Detlef K Bartsch

Introduction: The present study aimed to examine the clinical implications of postoperative hyperamylasemia (POH) after partial pancreaticoduodenectomy (PD).

Methods: Data from all consecutive patients undergoing PD were obtained from a prospectively maintained database and reviewed. POH was defined as an elevation of serum pancreatic amylase above the upper limit of normal (53 U/L) on postoperative days 0-2. Clinically relevant POH (cr-POH) was defined as POH in patients with clinically relevant (Clavien-Dindo ≥ III) postoperative complications.

Results: POH occurred in 61 of 170 (35.9%) and cr-POH in 24 of 170 (14.1%) patients. Patients with POH had higher rates of clinically relevant postoperative pancreatic fistula (cr-POPF) (44.3 vs. 3.7%, p < 0.001) and clinically relevant postoperative complications than those without POH (39.3 vs. 21.1%, p = 0.001). Patients with cr-POH had higher C-reactive protein (CRP, milligrams per liter) levels on third (257.7 vs. 187.85 mg/L, p = 0.016) and fourth (222.5 vs. 151, p = 0.002) postoperative day (POD) than those with POH alone. Serum procalcitonin (PCT, micrograms per liter) levels on POD 2 (1.2 vs. 0.4 μg/L, p = 0.028) and POD 3 (0.85 vs. 0.4 μg/L, p = 0.001) were also higher in patients with cr-POH. Rates of cr-POPF in patients with cr-POH were higher than in those with POH alone (70.8 vs. 27%, p = 0.001). POH (OR 0.011, 95% CI: 0.001-0.097, p < 0.001) was an independent predictor of cr-POPF in the multivariable analysis. A high-risk pathology, defined as nonadenocarcinoma/nonchronic pancreatitis pathology (OR 0.277, 95% CI: 0.106-0.727, p = 0.009), and a small duct diameter (OR 0.333, 95% CI: 0.139-0.796, p = 0.013) were independent predictors of POH in the multivariable analysis.

Conclusion: POH is a frequent, but not always clinically relevant, finding after partial PD. Serum CRP and PCT levels in the early postoperative period can be used to identify patients with cr-POH. POH is an independent risk factor for increased postoperative morbidity, including cr-POPF, after partial PD.

本研究旨在探讨部分胰十二指肠切除术(PD)后高淀粉酶血症(POH)的临床意义。方法:从前瞻性维护的数据库中获得所有连续PD患者的数据并进行回顾。POH定义为术后0-2天血清胰淀粉酶高于正常上限(53 U/L)。临床相关POH (cr-POH)定义为有临床相关(Clavien-Dindo≥III)术后并发症的患者的POH。结果:170例患者中POH 61例(35.9%),cr-POH 24例(14.1%)。POH患者术后临床相关胰瘘(cr-POPF)发生率(44.3比3.7%,p < 0.001)和术后临床相关并发症发生率(39.3比21.1%,p = 0.001)均高于无POH患者。术后第3天(257.7 vs. 187.85 mg/L, p = 0.016)和第4天(222.5 vs. 151, p = 0.002), cr-POH患者的c反应蛋白(CRP,毫克/升)水平高于单纯POH患者。cr-POH患者血清降钙素原(PCT,微克/升)POD 2 (1.2 vs. 0.4 μg/L, p = 0.028)和POD 3 (0.85 vs. 0.4 μg/L, p = 0.001)水平也较高。cr-POH患者的cr-POPF发生率高于单纯POH患者(70.8 vs 27%, p = 0.001)。在多变量分析中,POH (OR 0.011, 95% CI: 0.001-0.097, p < 0.001)是cr-POPF的独立预测因子。在多变量分析中,高风险病理,定义为非腺癌/非慢性胰腺炎病理(OR 0.277, 95% CI: 0.106-0.727, p = 0.009)和小导管直径(OR 0.333, 95% CI: 0.139-0.796, p = 0.013)是POH的独立预测因子。结论:POH是部分PD后常见的,但并不总是与临床相关。术后早期血清CRP和PCT水平可用于鉴别cr-POH患者。POH是部分PD后术后发病率增加的独立危险因素,包括cr-POPF。
{"title":"Clinical Implications of Postoperative Hyperamylasemia after Partial Pancreaticoduodenectomy.","authors":"Ioannis Mintziras, Sabine Wächter, Jerena Manoharan, Veit Kanngiesser, Elisabeth Maurer, Detlef K Bartsch","doi":"10.1159/000526495","DOIUrl":"10.1159/000526495","url":null,"abstract":"<p><strong>Introduction: </strong>The present study aimed to examine the clinical implications of postoperative hyperamylasemia (POH) after partial pancreaticoduodenectomy (PD).</p><p><strong>Methods: </strong>Data from all consecutive patients undergoing PD were obtained from a prospectively maintained database and reviewed. POH was defined as an elevation of serum pancreatic amylase above the upper limit of normal (53 U/L) on postoperative days 0-2. Clinically relevant POH (cr-POH) was defined as POH in patients with clinically relevant (Clavien-Dindo ≥ III) postoperative complications.</p><p><strong>Results: </strong>POH occurred in 61 of 170 (35.9%) and cr-POH in 24 of 170 (14.1%) patients. Patients with POH had higher rates of clinically relevant postoperative pancreatic fistula (cr-POPF) (44.3 vs. 3.7%, <i>p</i> < 0.001) and clinically relevant postoperative complications than those without POH (39.3 vs. 21.1%, <i>p</i> = 0.001). Patients with cr-POH had higher C-reactive protein (CRP, milligrams per liter) levels on third (257.7 vs. 187.85 mg/L, <i>p</i> = 0.016) and fourth (222.5 vs. 151, <i>p</i> = 0.002) postoperative day (POD) than those with POH alone. Serum procalcitonin (PCT, micrograms per liter) levels on POD 2 (1.2 vs. 0.4 μg/L, <i>p</i> = 0.028) and POD 3 (0.85 vs. 0.4 μg/L, <i>p</i> = 0.001) were also higher in patients with cr-POH. Rates of cr-POPF in patients with cr-POH were higher than in those with POH alone (70.8 vs. 27%, <i>p</i> = 0.001). POH (OR 0.011, 95% CI: 0.001-0.097, <i>p</i> < 0.001) was an independent predictor of cr-POPF in the multivariable analysis. A high-risk pathology, defined as nonadenocarcinoma/nonchronic pancreatitis pathology (OR 0.277, 95% CI: 0.106-0.727, <i>p</i> = 0.009), and a small duct diameter (OR 0.333, 95% CI: 0.139-0.796, <i>p</i> = 0.013) were independent predictors of POH in the multivariable analysis.</p><p><strong>Conclusion: </strong>POH is a frequent, but not always clinically relevant, finding after partial PD. Serum CRP and PCT levels in the early postoperative period can be used to identify patients with cr-POH. POH is an independent risk factor for increased postoperative morbidity, including cr-POPF, after partial PD.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 6","pages":"384-392"},"PeriodicalIF":1.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10523441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Clinical Importance of Preoperative Rectal Swabs in Patients after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. 细胞减缩手术及腹腔高温化疗后术前直肠棉签检查的临床意义。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-12-01 Epub Date: 2022-08-18 DOI: 10.1159/000526001
Philippa Seika, Susanne Marz, Christine Geffers, Thomas Adam, Linda Feldbrügge, Maximilian Jara, Johann Pratschke, Beate Rau

Background: Surgical site infections are among the most common healthcare-associated infections, especially in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The aim of this retrospective study was to examine postoperative infectious complications according to preoperative screening findings of nasal and rectal swabs.

Methods: Two hundred four consecutive patients received nasal and rectal swab examination for multidrug-resistant (MDR) bacteria within 30 days before the operation in patients where CRS and HIPEC were planned. Inclusion criteria were as follows: confirmed peritoneal metastases (histologically and/or cytologically); age under 85 years; adequate renal, liver, and bone marrow function; no sign of infection preoperatively; resectable disease; and CRS and HIPEC procedure. If surgical site infection occurred, the microbial spectrum of the site was assessed. One hundred twenty-one patients (63 female [52.1%] and 58 male [47.9%]) met the criteria and were further analyzed retrospectively. Statistical correlations between postoperative complications and risk factors were investigated by univariate and multivariate analysis.

Results: Postoperative complications in total were observed in 57 patients (47.1%) with major complications (Clavien-Dindo grades 3-4) in 15 patients (12.4%) and infectious complications in 37 (30.6%) patients. The overall prevalence of nasal MRSA carriage was 3.28%, and the overall prevalence of rectal MDR bacteria carriage was 10.7%. In propensity score analysis, colonized patients compared to noncolonized patients showed increased total complications (CD1-5, p = 0.025), infectious complications (p = 0.028), surgical site infections (p = 0.022) as well as pneumonia (p = 0.016). Multivariate analysis showed that in addition to preoperative rectal colonization, American Society of Anesthesiologists score was a risk factor for postoperative complications.

Conclusions: Preoperative 3-MRGN and vancomycin-resistant enterococcus colonization were associated with increased complications and surgical site infections. Special antimicrobial treatment pathways are necessary for these patients to reduce postoperative complications due to colonization.

背景:手术部位感染是最常见的卫生保健相关感染之一,特别是在接受细胞减少手术(CRS)和腹腔热化疗(HIPEC)的患者中。本回顾性研究的目的是根据术前鼻腔和直肠拭子筛查结果检查术后感染并发症。方法:对计划行CRS和HIPEC的244例患者,在术前30天内连续进行鼻直肠多药耐药(MDR)菌拭子检查。纳入标准如下:确认腹膜转移(组织学和/或细胞学);年龄在85岁以下;肾、肝、骨髓功能良好;术前无感染迹象;可切除的疾病;CRS和HIPEC程序。如果发生手术部位感染,则评估该部位的微生物谱。121例患者(女性63例[52.1%],男性58例[47.9%])符合标准,并进行回顾性分析。通过单因素和多因素分析探讨术后并发症与危险因素的统计学相关性。结果:术后共发生并发症57例(47.1%),主要并发症(Clavien-Dindo分级3-4级)15例(12.4%),感染性并发症37例(30.6%)。鼻腔MRSA携带总体患病率为3.28%,直肠MDR细菌携带总体患病率为10.7%。在倾向评分分析中,与非定殖患者相比,定殖患者的总并发症(CD1-5, p = 0.025)、感染并发症(p = 0.028)、手术部位感染(p = 0.022)和肺炎(p = 0.016)均有所增加。多因素分析显示,除了术前直肠定植外,美国麻醉医师学会评分也是术后并发症的危险因素。结论:术前3-MRGN和万古霉素耐药肠球菌定植与并发症和手术部位感染增加有关。特殊的抗菌药物治疗途径对这些患者来说是必要的,以减少由于定植引起的术后并发症。
{"title":"The Clinical Importance of Preoperative Rectal Swabs in Patients after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.","authors":"Philippa Seika, Susanne Marz, Christine Geffers, Thomas Adam, Linda Feldbrügge, Maximilian Jara, Johann Pratschke, Beate Rau","doi":"10.1159/000526001","DOIUrl":"10.1159/000526001","url":null,"abstract":"<p><strong>Background: </strong>Surgical site infections are among the most common healthcare-associated infections, especially in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The aim of this retrospective study was to examine postoperative infectious complications according to preoperative screening findings of nasal and rectal swabs.</p><p><strong>Methods: </strong>Two hundred four consecutive patients received nasal and rectal swab examination for multidrug-resistant (MDR) bacteria within 30 days before the operation in patients where CRS and HIPEC were planned. Inclusion criteria were as follows: confirmed peritoneal metastases (histologically and/or cytologically); age under 85 years; adequate renal, liver, and bone marrow function; no sign of infection preoperatively; resectable disease; and CRS and HIPEC procedure. If surgical site infection occurred, the microbial spectrum of the site was assessed. One hundred twenty-one patients (63 female [52.1%] and 58 male [47.9%]) met the criteria and were further analyzed retrospectively. Statistical correlations between postoperative complications and risk factors were investigated by univariate and multivariate analysis.</p><p><strong>Results: </strong>Postoperative complications in total were observed in 57 patients (47.1%) with major complications (Clavien-Dindo grades 3-4) in 15 patients (12.4%) and infectious complications in 37 (30.6%) patients. The overall prevalence of nasal MRSA carriage was 3.28%, and the overall prevalence of rectal MDR bacteria carriage was 10.7%. In propensity score analysis, colonized patients compared to noncolonized patients showed increased total complications (CD1-5, <i>p</i> = 0.025), infectious complications (<i>p</i> = 0.028), surgical site infections (<i>p</i> = 0.022) as well as pneumonia (<i>p</i> = 0.016). Multivariate analysis showed that in addition to preoperative rectal colonization, American Society of Anesthesiologists score was a risk factor for postoperative complications.</p><p><strong>Conclusions: </strong>Preoperative 3-MRGN and vancomycin-resistant enterococcus colonization were associated with increased complications and surgical site infections. Special antimicrobial treatment pathways are necessary for these patients to reduce postoperative complications due to colonization.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 6","pages":"376-383"},"PeriodicalIF":1.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10523440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopic Accessibility of the Biliary System in the Postoperative Situs. 术后胆道系统的内镜可达性
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-10-01 Epub Date: 2022-10-21 DOI: 10.1159/000526723
Benedikt Aulinger, Kerstin Schütte, Christian Schulz

Background: Alterations in the anatomy of the upper gastrointestinal tract may pose a challenge to the endoscopist, especially if interventions to the biliary system are indicated in patients with altered continuity of the gastrointestinal tract, impeding to reach the papilla with conventional ERC techniques. The success of any endoscopic intervention in this setting depends on optimal knowledge on the postoperative anatomy in each individual patient.

Summary: If conventional endoscopic retrograde cholangiopancreaticography is impossible, biliary tree access can be achieved by applying novel techniques including endosonography-directed approaches, overtube-assisted approaches or spiral enteroscopy to reach the papilla or biliodigestive anastomosis in case of long limbs, percutaneous or even hybrid approaches. This review gives an overview of the most common techniques.

Key message: The choice of endoscopic approach should be individual in each patient, taking indication and urgency, type of anatomic alteration, local expertise, patients' characteristics and preferences as well as prognosis into account. Early interdisciplinary discussion is essential to choose the procedure with the optimal risk-benefit ratio in the individual patient.

背景:上消化道解剖结构的改变可能对内镜医师构成挑战,特别是当胃肠道连续性改变的患者需要对胆道系统进行干预时,传统的ERC技术无法到达乳头。在这种情况下,任何内镜干预的成功取决于每个患者对术后解剖的最佳了解。摘要:如果传统的内镜逆行胆管胰管造影无法实现,在长肢、经皮甚至混合入路的情况下,可以通过应用新型技术,包括内镜引导入路、管上辅助入路或螺旋肠镜到达乳头或胆道消化吻合口,实现胆道树通路。这篇综述概述了最常见的技术。关键信息:内镜入路的选择应因人而异,考虑适应证和紧急程度、解剖改变类型、当地专业知识、患者的特点和偏好以及预后。早期跨学科的讨论对于选择具有最佳风险-收益比的手术是必要的。
{"title":"Endoscopic Accessibility of the Biliary System in the Postoperative Situs.","authors":"Benedikt Aulinger, Kerstin Schütte, Christian Schulz","doi":"10.1159/000526723","DOIUrl":"10.1159/000526723","url":null,"abstract":"<p><strong>Background: </strong>Alterations in the anatomy of the upper gastrointestinal tract may pose a challenge to the endoscopist, especially if interventions to the biliary system are indicated in patients with altered continuity of the gastrointestinal tract, impeding to reach the papilla with conventional ERC techniques. The success of any endoscopic intervention in this setting depends on optimal knowledge on the postoperative anatomy in each individual patient.</p><p><strong>Summary: </strong>If conventional endoscopic retrograde cholangiopancreaticography is impossible, biliary tree access can be achieved by applying novel techniques including endosonography-directed approaches, overtube-assisted approaches or spiral enteroscopy to reach the papilla or biliodigestive anastomosis in case of long limbs, percutaneous or even hybrid approaches. This review gives an overview of the most common techniques.</p><p><strong>Key message: </strong>The choice of endoscopic approach should be individual in each patient, taking indication and urgency, type of anatomic alteration, local expertise, patients' characteristics and preferences as well as prognosis into account. Early interdisciplinary discussion is essential to choose the procedure with the optimal risk-benefit ratio in the individual patient.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 1","pages":"328-333"},"PeriodicalIF":1.9,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41958321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-Tailored Approach for Enhanced Recovery after Surgery. 患者量身定制的方法提高术后恢复
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-10-01 Epub Date: 2022-10-13 DOI: 10.1159/000526692
Steffen Seyfried, Florian Herrle, Patrick Téoule, Alexander Betzler, Christoph Reissfelder

Background: Enhanced recovery after surgery (ERAS®) is increasingly finding its way into clinical practice. ERAS® protocols have not been universally adopted, and they have often been criticized for being difficult to implement. So, the question for more tailor-made approaches arises.

Methods: We conducted a literature search on March 16, 2022, using the following search string, which was modified to fit the input of each of the queried databases: ("ERAS®" or "enhanced recovery after surgery" or "fast recovery" or "fast track") and ("tailored" or "individual").

Results: Despite the massive increase in general hits on the subject, stratification according to phenotypic characteristics such as age or a classification according to disease patterns in the sense of specific guidelines is still fundamentally apparent. Evidence suggests that generic protocols can be followed by almost all patients. Prehabilitation, in particular, can be used as an adaptive tool.

Conclusion: ERAS® works only in the totality of its tools and can be followed by almost all patients. Prehabilitation is more adaptive and can also increase adherence to ERAS® protocols. A tailored program outside of disease-specific pathways does not seem to be useful.

背景:增强术后恢复(ERAS®)越来越多地进入临床实践。ERAS®协议尚未得到普遍采用,而且经常被批评难以实施。因此,出现了更为量身定制的方法的问题。方法:我们于2022年3月16日使用以下搜索字符串进行了文献搜索,并对其进行了修改,以适应每个查询数据库的输入:(“ERAS®”或“术后增强恢复”或“快速恢复”)和(“量身定制”或“个人”)。结果:尽管受试者的总体命中率大幅增加,但根据表型特征(如年龄)进行分层或根据特定指南意义上的疾病模式进行分类仍然从根本上是明显的。有证据表明,几乎所有患者都可以遵循通用方案。预适应训练尤其可以作为一种适应性工具。结论:ERAS®仅在其全部工具中有效,几乎所有患者都可以使用。预适应能力更强,也可以增加对ERAS®协议的遵守。在疾病特异性途径之外的量身定制的程序似乎没有用处。
{"title":"Patient-Tailored Approach for Enhanced Recovery after Surgery.","authors":"Steffen Seyfried, Florian Herrle, Patrick Téoule, Alexander Betzler, Christoph Reissfelder","doi":"10.1159/000526692","DOIUrl":"10.1159/000526692","url":null,"abstract":"<p><strong>Background: </strong>Enhanced recovery after surgery (ERAS®) is increasingly finding its way into clinical practice. ERAS® protocols have not been universally adopted, and they have often been criticized for being difficult to implement. So, the question for more tailor-made approaches arises.</p><p><strong>Methods: </strong>We conducted a literature search on March 16, 2022, using the following search string, which was modified to fit the input of each of the queried databases: (\"ERAS®\" or \"enhanced recovery after surgery\" or \"fast recovery\" or \"fast track\") and (\"tailored\" or \"individual\").</p><p><strong>Results: </strong>Despite the massive increase in general hits on the subject, stratification according to phenotypic characteristics such as age or a classification according to disease patterns in the sense of specific guidelines is still fundamentally apparent. Evidence suggests that generic protocols can be followed by almost all patients. Prehabilitation, in particular, can be used as an adaptive tool.</p><p><strong>Conclusion: </strong>ERAS® works only in the totality of its tools and can be followed by almost all patients. Prehabilitation is more adaptive and can also increase adherence to ERAS® protocols. A tailored program outside of disease-specific pathways does not seem to be useful.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 1","pages":"322-327"},"PeriodicalIF":1.9,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42275376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PharmaNews PharmaNews
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-10-01 DOI: 10.1159/000527264
Jyseleca® (Filgotinib 200 mgund 100 mg-Filmtabletten) ist zugelassen zur Behandlung von erwachsenen Patient*innen mit mittelschwerer bis schwerer aktiver rheumatoider Arthritis (RA), die auf ein oder mehrere krankheitsmodifizierende Antirheumatika (DMARDs) unzureichend angesprochen oder diese nicht vertragen haben [1]. Eine beim EULAR 2022 vorgestellte Post-hoc-Analyse der Studie FINCH 4 – einer Verlängerungsstudie der zulassungsrelevanten Phase-3-Studien FINCH 1 bis 3 – verglich Patient*innen, die zu Beginn der Eingangsstudie ≥ 75 Jahre alt waren (n = 102) mit Patient*innen im Alter < 75 Jahre (n = 2 627)a. Bis Woche 48 der Verlängerungsstudie war Filgotinib in beiden Alterskohorten effektiv. Die Verträglichkeit von Filgotinib war gut, bei Patient*innen ≥ 75 Jahre traten geringfügig mehr unerwünschte Ereignisse auf als bei Jüngeren. Als mögliche Gründe hierfür nennen die Autoren vermehrte Komorbiditäten bei Patient*innen ≥ 75 Jahre sowie die bei Älteren häufig reduzierte Nierenfunktion, die mit einer höheren Wirkstoffexposition einhergehen kann [2].
Jyseleca®(Filgotinib 200 mgund 100 mg-Filmtabletten),是允许用于治疗成人病人*里面mittelschwerer到严重的现役风湿性关节炎(RA)一个或多个krankheitsmodifizierende Antirheumatika (DMARDs)不足以解决或者消化不良的人[1].一个在2022 EULAR想象Post-hoc-Analyse芬奇研究4——一个Verlängerungsstudie zulassungsrelevanten Phase-3-Studien芬奇比较1至3 -病人*里面的起头,Eingangsstudie≥75岁(n = 102) *在病人年龄< 75年(n = 2 627) a .直到48天的延寿实验才有效。Filgotinib是好,对于病人的肤质*内≥75年,已略高于不良的事件为成为新青年.作为可能的原因称作者增加Komorbiditäten在病人*内≥75年以及在老年人经常降低的不同,同时能有更高Wirkstoffexposition [2] .
{"title":"PharmaNews","authors":"","doi":"10.1159/000527264","DOIUrl":"https://doi.org/10.1159/000527264","url":null,"abstract":"Jyseleca® (Filgotinib 200 mgund 100 mg-Filmtabletten) ist zugelassen zur Behandlung von erwachsenen Patient*innen mit mittelschwerer bis schwerer aktiver rheumatoider Arthritis (RA), die auf ein oder mehrere krankheitsmodifizierende Antirheumatika (DMARDs) unzureichend angesprochen oder diese nicht vertragen haben [1]. Eine beim EULAR 2022 vorgestellte Post-hoc-Analyse der Studie FINCH 4 – einer Verlängerungsstudie der zulassungsrelevanten Phase-3-Studien FINCH 1 bis 3 – verglich Patient*innen, die zu Beginn der Eingangsstudie ≥ 75 Jahre alt waren (n = 102) mit Patient*innen im Alter < 75 Jahre (n = 2 627)a. Bis Woche 48 der Verlängerungsstudie war Filgotinib in beiden Alterskohorten effektiv. Die Verträglichkeit von Filgotinib war gut, bei Patient*innen ≥ 75 Jahre traten geringfügig mehr unerwünschte Ereignisse auf als bei Jüngeren. Als mögliche Gründe hierfür nennen die Autoren vermehrte Komorbiditäten bei Patient*innen ≥ 75 Jahre sowie die bei Älteren häufig reduzierte Nierenfunktion, die mit einer höheren Wirkstoffexposition einhergehen kann [2].","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 1","pages":"367 - 368"},"PeriodicalIF":1.9,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46755180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Need of Antimicrobial Stewardship in Post-Operative Infectious Complications of Abdominal Surgery. 腹部手术术后感染并发症抗菌药物管理的必要性
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-10-01 Epub Date: 2022-10-21 DOI: 10.1159/000526785
Wilfried Obst, Torben Esser, Achim Jens Kaasch, Gernot Geginat, Frank Meyer, Roland S Croner, Verena Keitel

Background: Post-operative infection is a common complication following abdominal surgery. The two most common infections are secondary peritonitis and surgical site infections, which lead to increased perioperative morbidity, prolonged hospitalization, higher mortality rates, and increased treatment costs. In addition to surgical procedures, treatment is based on effective antibiotic therapy. Due to increasing antimicrobial resistance, the correct use of antimicrobials is becoming more complex. Many initiatives call for the implementation of an antimicrobial stewardship (AMS) programme to optimize anti-infective therapy. The review article summarizes current recommendations in anti-infective therapy of post-operative peritonitis and surgical site infections and highlights the importance of an AMS programme in abdominal surgery.

Summary: Larger studies evaluating the benefit of AMS in abdominal surgery are lacking. However, national and international guidelines have formulated appropriate recommendations for the rational use of antibiotics in post-operative peritonitis and surgical site infections. The rate of post-operative infections can be significantly reduced by perioperative antibiotic prophylaxis. The increase in multidrug-resistant bacteria complicates anti-infective therapy for post-operative infections. Analysis of local susceptibility patterns helps choose an adequate empiric therapy. A high rate of extended-spectrum beta-lactamase-producing bacteria may necessitate the use of other reserve antibiotics in addition to carbapenems, which are approved for the treatment of complicated intra-abdominal infections. A key role for the AMS team is the subsequent de-escalation of antibiotic therapy which limits the use of unnecessary broad-spectrum antibiotics.

Key messages: The increase in multidrug-resistant bacteria poses challenges for abdominal surgery. Post-operative infections should be treated by an interdisciplinary team of surgeons and specialists for AMS.

背景:术后感染是腹部手术后常见的并发症。两种最常见的感染是继发性腹膜炎和手术部位感染,这会导致围手术期发病率增加、住院时间延长、死亡率升高和治疗费用增加。除了外科手术,治疗是基于有效的抗生素治疗。由于抗微生物耐药性的增加,正确使用抗微生物药物变得越来越复杂。许多倡议要求实施抗菌管理(AMS)计划,以优化抗感染治疗。这篇综述文章总结了目前对术后腹膜炎和手术部位感染的抗感染治疗的建议,并强调了AMS计划在腹部手术中的重要性。总结:目前缺乏评估AMS在腹部手术中益处的大型研究。然而,国家和国际指南为术后腹膜炎和手术部位感染合理使用抗生素制定了适当的建议。围手术期抗生素预防可以显著降低术后感染率。耐多药细菌的增加使术后感染的抗感染治疗变得复杂。对局部易感性模式的分析有助于选择适当的经验疗法。高比率的超广谱β-内酰胺酶产生菌可能需要使用除碳青霉烯类抗生素外的其他储备抗生素,碳青霉烯属抗生素已被批准用于治疗复杂的腹腔内感染。AMS团队的一个关键作用是随后减少抗生素治疗,从而限制不必要的广谱抗生素的使用。关键信息:耐多药细菌的增加给腹部手术带来了挑战。术后感染应由AMS的外科医生和专家组成的跨学科团队进行治疗。
{"title":"The Need of Antimicrobial Stewardship in Post-Operative Infectious Complications of Abdominal Surgery.","authors":"Wilfried Obst, Torben Esser, Achim Jens Kaasch, Gernot Geginat, Frank Meyer, Roland S Croner, Verena Keitel","doi":"10.1159/000526785","DOIUrl":"10.1159/000526785","url":null,"abstract":"<p><strong>Background: </strong>Post-operative infection is a common complication following abdominal surgery. The two most common infections are secondary peritonitis and surgical site infections, which lead to increased perioperative morbidity, prolonged hospitalization, higher mortality rates, and increased treatment costs. In addition to surgical procedures, treatment is based on effective antibiotic therapy. Due to increasing antimicrobial resistance, the correct use of antimicrobials is becoming more complex. Many initiatives call for the implementation of an antimicrobial stewardship (AMS) programme to optimize anti-infective therapy. The review article summarizes current recommendations in anti-infective therapy of post-operative peritonitis and surgical site infections and highlights the importance of an AMS programme in abdominal surgery.</p><p><strong>Summary: </strong>Larger studies evaluating the benefit of AMS in abdominal surgery are lacking. However, national and international guidelines have formulated appropriate recommendations for the rational use of antibiotics in post-operative peritonitis and surgical site infections. The rate of post-operative infections can be significantly reduced by perioperative antibiotic prophylaxis. The increase in multidrug-resistant bacteria complicates anti-infective therapy for post-operative infections. Analysis of local susceptibility patterns helps choose an adequate empiric therapy. A high rate of extended-spectrum beta-lactamase-producing bacteria may necessitate the use of other reserve antibiotics in addition to carbapenems, which are approved for the treatment of complicated intra-abdominal infections. A key role for the AMS team is the subsequent de-escalation of antibiotic therapy which limits the use of unnecessary broad-spectrum antibiotics.</p><p><strong>Key messages: </strong>The increase in multidrug-resistant bacteria poses challenges for abdominal surgery. Post-operative infections should be treated by an interdisciplinary team of surgeons and specialists for AMS.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 1","pages":"345-353"},"PeriodicalIF":1.9,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46207876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Visceral Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1